Create your Personal Health Record and unlock support built around you

  • Treatments and trials you qualify for
  • Education for your stage of care
  • Financial support for your medications
  • Solutions to your side effects
Measurable Residual Disease in ALL image

Measurable Residual Disease in ALL

Sep 17, 2026
02:30PM - 03:30PM EDT
Online Event
Overview

With all the different cancer monitoring and detection tools out there, it can sometimes be hard to narrow down which ones work for your disease. Join HealthTree as we hear from Dr. Namrata Chandhok as she discusses measurable residual disease in ALL.

Agenda
2:30 PM
Introduction
Eliza Prickett, MPH

Eliza introduces the agenda of the event and our featured speaker Dr. Namrata Chandhok

2:35 PM
Presentation
Dr. Namrata Chandhok

Dr. Namrata Chandhok talks about MRD for ALL patients

3:05 PM
Questions and Answers
Audience

Come with your questions we will answer them!

Speakers & Moderators
Healthtree contact Eliza Prickett, MPH

Eliza Prickett, MPH

Eliza joined HealthTree in March 2026 as the Leukemia Patient Health Education Manager. Prior to joining HealthTree, she completed a Master’s Degree in Public Health from Brigham Young University and worked with a variety of underserved populations in government and healthcare settings, including Americorps and Utah Health Department. When not in office, Eliza enjoys reading, writing and learning new things about the world.
Healthtree contact Dr. Namrata Chandhok

Dr. Namrata Chandhok

Namrata S. Chandhok is an Assistant Professor of Clinical Medicine in the Division of Hematology at the University of Miami Miller School of Medicine, clinical co-leader of the myeloid malignancies program, and member of the Cancer Epigenetics Program at Sylvester Comprehensive Cancer Center. She has a longstanding interest in cancer biology with experience in clinical-translational investigation with a clinical focus on the care of patients with myeloid malignancies. Her career goals include improving our understanding of the evolution of myeloid malignancies, identifying disease characteristics that can be exploited for therapeutic gain and clinically applying innovative therapies to improve outcomes for patients with these diseases. To this end, she has an active clinical trial portfolio that includes investigator-initiated studies with biologically relevant correlative studies, as well as larger industry-sponsored, multi-institutional collaborative efforts. Dr. Chandhok is also working to identify pre-leukemic biomarkers that may be acted upon for disease prevention. At Sylvester Cancer Center she spearheaded the development of a clonal hematopoiesis program to advance the care of patients who may be predisposed to the development of aggressive hematologic malignancies. Within the areas of drug development and cancer prevention, Dr. Chandhok aspires to further our understanding of disease biology in varied populations to provide more personalized cancer care.